Pirenoxine ophthalmic suspension 0.005% "Santen" (ピレノキシン懸濁性点眼液0.005%「参天」) Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

pirenoxine ophthalmic suspension 0.005% "santen" (ピレノキシン懸濁性点眼液0.005%「参天」)

santen pharmaceutical co.,ltd. - pirenoxine - orange when shaken, ophthalmic suspension, 5ml, (bottle) bright orange, (cap) white

Pranoprofen ophthalmic solution 0.1% "Santen" (プラノプロフェン点眼液0.1%「参天」) Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

pranoprofen ophthalmic solution 0.1% "santen" (プラノプロフェン点眼液0.1%「参天」)

santen pharmaceutical co.,ltd. - pranoprofen - limpid and colorless, ophthalmic solution, 5ml, (bottle) clear and colorless, (cap) very pale yellow green

Rebamipide ophthalmic suspension 2% "Santen" (レバミピド懸濁性点眼液2％「参天」) Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

rebamipide ophthalmic suspension 2% "santen" (レバミピド懸濁性点眼液2％「参天」)

santen pharmaceutical co.,ltd. - rebamipide - white when shaken, ophthalmic suspension, 5ml, (bottle) clear and colorless, (cap) white [one line of deep purple over the light pink label]

CO-DIOVAN 8012.5 MG FILM COATED TABLETS Israël - anglais - Ministry of Health

co-diovan 8012.5 mg film coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

CO-DIOVAN 16012.5 MG FILM-COATED TABLETS Israël - anglais - Ministry of Health

co-diovan 16012.5 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

CO-DIOVAN 16025 MG FILM-COATED TABLETS Israël - anglais - Ministry of Health

co-diovan 16025 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

CO-DIOVAN 320/12.5 mg/mg Film Coated Tablet Irlande - anglais - HPRA (Health Products Regulatory Authority)

co-diovan 320/12.5 mg/mg film coated tablet

novartis pharmaceuticals uk ltd - valsartan, hydrochlorothiazide, micronized - film coated tablet - 320/12.5 mg/mg - angiotensin ii antagonists and diuretics

CO-DIOVAN 320/25 mg/mg Film Coated Tablet Irlande - anglais - HPRA (Health Products Regulatory Authority)

co-diovan 320/25 mg/mg film coated tablet

novartis pharmaceuticals uk ltd - valsartan, hydrochlorothiazide, micronized - film coated tablet - 320/25 mg/mg - angiotensin ii antagonists and diuretics

TIMOPTOL OPHTHALMIC SOLUTION 0.5% Singapour - anglais - HSA (Health Sciences Authority)

timoptol ophthalmic solution 0.5%

santen pharmaceutical asia pte. ltd. - timolol maleate 6.83 mg eqv timolol - solution - 0.50% - timolol maleate 6.83 mg eqv timolol 5.00 mg/ml

CO-DIOVAN 320/25 mg valsartan 320 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack Australie - anglais - Department of Health (Therapeutic Goods Administration)

co-diovan 320/25 mg valsartan 320 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.